BioCryst Pharmaceuticals Updated Its Agreement With Torii Pharmaceutica For ORLADEYO In Japan; BioCryst Japan K.K. Responsible For All Commercial Promotion Activities And Torii Will Be Responsible For Hereditary Angioedema Disease Awareness Activities
BioCryst Pharmaceuticals Updated Its Agreement With Torii Pharmaceutica For ORLADEYO In Japan; BioCryst Japan K.K. Responsible For All Commercial Promotion Activities And Torii Will Be Responsible For Hereditary Angioedema Disease Awareness Activities
BioCryst Pharmicals更新了與Torii Pharmacetica在日本的ORLADEYO協議;BioCryst Japan K.K. 負責所有商業促銷活動,Torii 將負責遺傳性血管性水腫疾病宣傳活動
BioCryst Pharmicals更新了與Torii Pharmacetica在日本的ORLADEYO協議;BioCryst Japan K.K. 負責所有商業促銷活動,Torii 將負責遺傳性血管性水腫疾病宣傳活動